Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBT Margin (2019 - 2023)

Benitec Biopharma's EBT Margin history spans 5 years, with the latest figure at 65114.29% for Q2 2023.

  • For Q2 2023, EBT Margin changed N/A year-over-year to 65114.29%; the TTM value through Mar 2024 reached 307371.43%, down 27898319.0%, while the annual FY2023 figure was 25485.33%, 98396.0% down from the prior year.
  • EBT Margin for Q2 2023 was 65114.29% at Benitec Biopharma, down from 8051.85% in the prior quarter.
  • Across five years, EBT Margin topped out at 7031.71% in Q2 2020 and bottomed at 379500.0% in Q1 2021.
  • The 5-year median for EBT Margin is 8051.85% (2023), against an average of 80757.75%.
  • The largest annual shift saw EBT Margin crashed -37202143bps in 2021 before it soared 37227292bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 2719.48% in 2019, then plummeted by -11891bps to 326100.0% in 2020, then soared by 94bps to 19384.0% in 2021, then plummeted by -107bps to 40135.71% in 2022, then tumbled by -62bps to 65114.29% in 2023.
  • Per Business Quant, the three most recent readings for BNTC's EBT Margin are 65114.29% (Q2 2023), 8051.85% (Q1 2023), and 40135.71% (Q4 2022).